Journal of Endocrinological Investigation

, Volume 3, Issue 2, pp 149–153 | Cite as

Bromocriptine acute effect on insulin, glucagon and growth hormone levels in acromegalic patients

  • Domenico Fedele
  • M. Molinari
  • A. Meneghel
  • A. Valerio
  • M. Muggeo
  • A. Tiengo


It has been shown that L-dopa or dopamine administration influences glucose metabolism, as well as insulin and glucagon release in man. In the present study, the effect of bromocriptine (CB-154), a long-acting dopamine agonist, on insulin, glucagon and growth hormone secretion in 32 acromegalic patients was investigated. Glucose, insulin and plasma glucagon levels were not modified following administration of bromocriptine or placebo. Moreover, plasma GH levels were decreased by more than 50% in 18 of the 32 acromegalics. Mean GH levels were significantly lower with respect to levels observed following placebo at 60 min to the end of the test (p < 0.001). Administration of a double dose of CB-154 (5 mg po) one hour before arginine test did not affect insulin or glucagon secretion with respect to levels observed during arginine alone. In addition, there was a fall in GH levels similar to that observed following administration of bromocriptine alone. These findings suggest that bromocriptine in itself does not exert a direct action on insulin and glucagon release. Improvement in glucose tolerance and reduction in insulin secretion observed following prolonged CB-154 treatment in acromegalic patients are probably due to a simultaneous inhibition of GH secretion or to other peripheral effects of bromocriptine.


Bromocriptine arginine test insulin glucagon growth hormone acromegaly 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Corrodi H., Fuxe K., Hökfelt T., Lidbrink P., Ungerstedt U. Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons. J. Pharm. Pharmacol. 25: 409, 1973.PubMedCrossRefGoogle Scholar
  2. 2.
    Liuzzi A., Chiodini P.G., Botalla L., Cremascoli G., Müller E.E., Silvestrini F. Decreased plasma growth hormone (GH) levels in acromegalics following CB-154 (2-Br-α-ergocryptine) administration. J. Clin. Endocrinol. Metab. 38: 910, 1974.PubMedCrossRefGoogle Scholar
  3. 3.
    Camanni F., Massara F., Belforte L., Molinatti G.M. Changes in plasma growth hormone levels in normal and acromegalic subjects following administration of 2-Bromo-d-Ergocryptine. J. Clin. Endocrinol. Metab. 40: 363, 1975.PubMedCrossRefGoogle Scholar
  4. 4.
    Thorner M.O., Chait A., Aitken M., Benker G., Bloom S.R., Mortimer C.H., Sanders P., Stuart Mason A., Besser G.M. Bromocriptine treatment of acromegaly. Br. Med. J. 1: 299, 1975.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Sachdev Y., Gomez-Pan A., Tunbridge W.M.G., Duns A., Weightman D.R., Hall R. Bromocriptine therapy in acromegaly. Lancet 2: 1164, 1975.PubMedCrossRefGoogle Scholar
  6. 6.
    Belforte L., Camanni F., Chiodini P.G., Liuzzi A., Massara F., Molinatti G.M., Müller E.E., Silvestrini F. Long-term treatment with 2-Br-α-ergocryptine in acromegaly. Acta Endocrinol. (Kbh.) 85: 235, 1977.Google Scholar
  7. 7.
    Fossati P., Asfour M., Brion-Brevan B., Fourlinnie J.CI., Cappoen J.P., Dalle-Furnari M.A. Effet thérapeutiques de la bromocriptine chez 10 acromégales. Ann. Endocrinol. (Paris) 37: 299, 1976.Google Scholar
  8. 8.
    Halse J., Haugen H.N., Böhmer T. Bromocriptine treatment in acromegaly: clinical and biochemical effects. Acta Endocrinol. (Kbh.) 86: 464, 1977.Google Scholar
  9. 9.
    Faloona G.R., Unger R.H. Glucagon. In: Jaffe B.M., Behrmon H.R. (Eds.), Methods of hormone radioimmunoassay. Academic Press Inc. New York, 1974, p. 317.Google Scholar
  10. 10.
    Herbert U., Lau K.S., Gottlieb C.W., Bleicher S.J. Coated-charcoal immunoassay of insulin. J. Clin. Endocrinol. Metab. 25:1375, 1965.PubMedCrossRefGoogle Scholar
  11. 11.
    Molinatti G.M., Massara F., Strumia E., Pennisi F., Scassellati G.A., Vancheri L. Radioimmunoassay of human growth hormone. J. Nucl. Biol. Med. All. Sci. 13: 26, 1969.Google Scholar
  12. 12.
    Cegrell L. The occurrence of biogenic monoamines in the mammalian endocrine pancreas. Acta Physiol. Scand. (Suppl.) 314:1, 1968.Google Scholar
  13. 13.
    Calne D.B., Karoum F., Ruthven C.R.J. The metabolism of orally administered L-dopa in parkinsonism. Br. J. Pharmacol. 37: 37, 1969.Google Scholar
  14. 14.
    Rayfield E.J., George D.T., Eichner H.L., Hsu H.T. L-dopa stimulation of glucagon secretion in man. N. Engl. J. Med. 18:589, 1975.CrossRefGoogle Scholar
  15. 15.
    Lorenzi M., Tsalikian E., Bohannon N.V., Gerich J.E., Karan J.H., Forsham P.H. Differential sensitivity of pancreatic glucagon to L-dopa and apomorphine in man. Evidence against a direct dopaminergic mechanism of stimulation. Proceedings of the 5th International Congress of Endocrinology, Hamburg 1976, p. 341, (Abstract).Google Scholar
  16. 16.
    Thorner M.O., Wass J.A.H., Jones A., Bloom S.R., McLeod R.M. Effect of piribedil infusions on circulating GH, insulin, glucagon, Cortisol and blood sugar in man. Proceedings of the 5th International Congress of Endocrinology, Hamburg 1976, p. 24 (Abstract).Google Scholar
  17. 17.
    Landgraf R., Landgraf-Leurs M.M.C., Weissman A., Hörl R., Von Werder K., Scriba P.C. Prolactin: A diabetogenic hormone. Diabetologia, 13:99, 1977.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1980

Authors and Affiliations

  • Domenico Fedele
    • 1
  • M. Molinari
    • 1
  • A. Meneghel
    • 1
  • A. Valerio
    • 1
  • M. Muggeo
    • 1
  • A. Tiengo
    • 1
  1. 1.Dipartimento di Medicina Interna, Divisione di Gerontologia e di Malattie Metaboliche, PoliclinicoUniversità di PadovaPadovaItaly

Personalised recommendations